Stock News

KalVista Pharmaceuticals, Inc. (KALV) EPS Estimated At $-0.51

Analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to report $-0.51 EPS on December, 13.They anticipate $0.01 EPS change or 2.00 % from last quarter’s $-0.5 EPS. After having $-0.47 EPS previously, KalVista Pharmaceuticals, Inc.’s analysts see 8.51 % EPS growth. The stock decreased 0.79% or $0.15 during the last trading session, reaching $18.82. About 25,566 shares traded. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has risen 81.98% since November 10, 2017 and is uptrending. It has outperformed by 66.36% the S&P500.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company has market cap of $323.32 million. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. It currently has negative earnings. The Company’s products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein.

More recent KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) news were published by: Nasdaq.com which released: “Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive …” on October 18, 2018. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For October 30, 2018” on October 30, 2018. Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: October 15, 2018 was also an interesting one.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*